Chardan Capital Maintains Buy Rating on Arrowhead Pharma, Sets $115 Target
Chardan Capital maintained its Buy rating and $115 price target for Arrowhead Pharmaceuticals. The target implies 97.0% upside from the Oct. 14 close of $58.37.
Chardan Capital maintained its Buy rating and $115 price target for Arrowhead Pharmaceuticals. The target implies 97.0% upside from the Oct. 14 close of $58.37.